Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma
作者机构：Department of Hepatobiliary SurgeryFirst Affiliated Hospital of Third Military Medical University(Army Medical University)Chongqing 400038China Department of Hepatobiliary SurgeryFirst Affiliated Hospital of Third Military Medical University(Army Medical University)Jiangbei Area(The 958th Hospital of Chinese People's Liberation Army)Chongqing 400020China
出 版 物：《World Journal of Gastrointestinal Surgery》 (世界胃肠外科杂志（英文版）（电子版）)
年 卷 期：2024年第16卷第9期
页 面：2829-2841页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Hepatocellular carcinoma Transarterial chemoembolization,Therapeutic Immunotherapy Prognosis
摘 要：BACKGROUND Hepatocellular carcinoma(HCC)often presents as unresectable,necessitating effective treatment *** transarterial chemoembolization(TACE)with immunotherapy and targeted therapy has shown promise,yet real-world evidence is *** To investigate effectiveness and safety of TACE with tislelizumab±targeted therapy for unresectable HCC in real-world *** This retrospective study included patients with unresectable HCC receiving combined treatment of TACE and *** clinical outcomes included progression-free survival(PFS),overall survival(OS),objective response rate(ORR),and disease control rate(DCR).All patients were evaluated according to the mRECIST *** adverse event(AE)was also *** In this study of 56 patients with median follow-up of 10.9 months,7 had previous *** was administered before TACE in 21(37.50%)and after in 35(62.50%)patients,with 91.07%receiving concurrent targeted *** PFS was 14.0(95%CI:7.0-18.00)months,and OS was 28(95%CI:2.94-53.05)*** with prior immunotherapy had shorter PFS(6 vs.18 months,P=0.006).Overall ORR and DCR were 82.14%and 87.50%.Grade≥3 treatment-related AEs included increased alanine aminotransferase(8.93%),aspartate aminotransferase(10.71%),and total bilirubin(3.57%).CONCLUSION The combination of TACE and tislelizumab,with or without targeted therapy,demonstrated promising efficacy and safety in unresectable HCC,especially in immunotherapy-naive patients,warranting further prospective validation studies.
维普期刊数据库